×
About 10 results

Emerging Data on Type 1 Diabetes and COVID-19 Reassuring 
https://www.staging.medscape.com/viewarticle/938883

Oct 8th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Most people with type 1 diabetes do not appear to be at increased risk for hospitalization or death from COVID-19 compared to the general population, new research suggests. Two retrospective studies of type 1 diabetes and COVID-19 were published in the October issue of Diabetes Care. One, by Rom...

Emerging Data on Type 1 Diabetes and COVID-19 Reassuring 
https://www.medscape.com/viewarticle/938883

Oct 8th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Most people with type 1 diabetes do not appear to be at increased risk for hospitalization or death from COVID-19 compared to the general population, new research suggests. No Evidence of Increased Hospitalization In the Belgian study, medical records were analyzed for a total of 2336 patients w...

Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda
https://www.medscape.com/viewarticle/937485

Sep 15th, 2020 - This year's virtual meeting of the European Association for the Study of Diabetes (EASD) offers new data and insights regarding the use of newer glucose-lowering agents for treating people with, and without, diabetes, as well as updates on diabetes technology, a symposium on COVID-19, and much more. The meeting takes place live online September 22-25, Central European time, because it was to ha...

Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda
https://www.staging.medscape.com/viewarticle/937485

Sep 15th, 2020 - This year's virtual meeting of the European Association for the Study of Diabetes (EASD) offers new data and insights regarding the use of newer glucose-lowering agents for treating people with, and without, diabetes, as well as updates on diabetes technology, a symposium on COVID-19, and much more. The meeting takes place live online September 22-25, Central European time, because it was to ha...

Calcium Scoring Pinpoints Stenoses in Asymptomatic Diabetes
https://www.medscape.com/viewarticle/932471

Jun 16th, 2020 - For diabetes patients with no cardiovascular symptoms despite certain risk factors, incorporating coronary calcium scoring into a silent myocardial ischemia screening algorithm may be an effective and cost-conscious strategy that avoids missed coronary stenoses suitable for revascularization, results of a recent study suggest. Zero patients in need of revascularization were missed in a risk str...

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
https://www.staging.medscape.com/viewarticle/927820

Mar 30th, 2020 - AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy of the drug, at the recommendation of an independent data monitoring committee. DAPA-CKD is an international, multicenter, randomized, double-blinded trial in 4,245 patients with stage 2-4 chronic kidney disease. Pat...

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
https://www.medscape.com/viewarticle/927820

Mar 30th, 2020 - AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy of the drug, at the recommendation of an independent data monitoring committee. DAPA-CKD is an international, multicenter, randomized, double-blinded trial in 4,245 patients with stage 2-4 chronic kidney disease. Pat...

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
https://emedicine.medscape.com/viewarticle/927820

AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy of the drug, at the recommendation of an independent data monitoring committee. DAPA-CKD is an international, multicenter, randomized, double-blinded trial in 4,245 patients with stage 2-4 chronic kidney disease. Pat...

Group-Based Trajectory of Body Shape From Ages 5 to 55 Years and Cardiometabolic Disease Risk in 2 US Cohorts
https://emedicine.medscape.com/viewarticle/889710

Abstract and Introduction Abstract The association of adiposity across the life span with cardiometabolic risk is not completely delineated. We used a group-based modeling approach to identify distinct trajectories of body shape from ages 5 years to 55 years among 84,792 women from the Nurses' Health Study (1976–2010) and 37,706 men from the Health Professionals Follow-up Study (1986–2010) and ...

Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program
https://emedicine.medscape.com/viewarticle/893867

Abstract and Introduction Abstract Context: It is unclear whether relative elevations in androgens or irregular menses (IM) are associated with greater cardiometabolic risk among women who are already overweight and glucose intolerant. Research Design and Methods: We conducted a secondary analysis of the Diabetes Prevention Program (DPP) and the Diabetes Prevention Program Outcomes Study (DPPOS...